Trials / Completed
CompletedNCT00402584
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in subjects with binge-eating disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sibutramine |
Timeline
- Start date
- 2000-08-01
- First posted
- 2006-11-22
- Last updated
- 2007-08-31
Source: ClinicalTrials.gov record NCT00402584. Inclusion in this directory is not an endorsement.